Χώρα: Καναδάς
Γλώσσα: Αγγλικά
Πηγή: Health Canada
OMEPRAZOLE
ASTRAZENECA CANADA INC
A02BC01
OMEPRAZOLE
10MG
CAPSULE (DELAYED RELEASE)
OMEPRAZOLE 10MG
ORAL
28
Prescription
PROTON-PUMP INHIBITORS
Active ingredient group (AIG) number: 0121643003; AHFS:
CANCELLED POST MARKET
2013-12-04
COPYRIGHT 1989, 2000, 2005 ASTRAZENECA CANADA INC. PRODUCT MONOGRAPH LOSEC ® (omeprazole delayed release capsules) 10 and 20 mg omeprazole H + , K + -ATPase Inhibitor AstraZeneca Canada Inc. 1004 Middlegate Road Mississauga, Ontario L4Y 1M4 www.astrazeneca.ca Date of Revision: April 5, 2013 Submission Control Number: 161843 LOSEC ® , LOSEC 1-2-3 A ® , LOSEC 1-2-3 M ® and the AstraZeneca logo are registered trademarks of the AstraZeneca group of companies. - 1 - COPYRIGHT 1989, 2000, 2005 ASTRAZENECA CANADA INC. PRODUCT MONOGRAPH NAME OF DRUG LOSEC ® (omeprazole delayed release capsules) 10 and 20 mg omeprazole THERAPEUTIC CLASSIFICATION H + , K + -ATPase Inhibitor NOTE: When used in combination with amoxicillin, clarithromycin or metronidazole, the Product Monographs for those agents must be consulted and followed. ACTIONS AND CLINICAL PHARMACOLOGY LOSEC (omeprazole) inhibits the gastric enzyme H + ,K + -ATPase (the proton pump) which catalyzes the exchange of H + and K + . It is effective in the inhibition of both basal acid secretion and stimulated acid secretion. The inhibition is dose-dependent. Daily oral doses of omeprazole 20 mg and higher showed a consistent and effective acid control. A mean reduction of 24-hour intragastric acidity of approximately 80% was achieved during repeated dosing of 20 mg daily. Treatment with LOSEC alone has been shown to suppress, but not eradicate _Helicobacter _ _pylori_ ( _H. pylori_ ), a bacterium that is strongly associated with acid peptic disease. Approximately 90 to 100% of patients with duodenal ulcers, and 80% of patients with gastric ulcers, are infected with _H. pylori_ . Clinical evidence indicates a synergistic effect between omeprazole and certain antibiotics in achieving eradication of _H. pylori_ . Eradication of _H. _ _pylori_ is associated with symptom relief, healing of mucosal lesions, decreased rate of duodenal ulcer recurrence and long-term remission of peptic ulcer disease, reducing the need for prolonged antisecretory therapy. There is no statisti Διαβάστε το πλήρες έγγραφο